Quoin Pharmaceuticals, Ltd. financial data

Symbol
QNRX on Nasdaq
Location
Kfar Saba
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 219% % -34%
Debt-to-equity 167% % 78%
Return On Equity -334% % -166%
Return On Assets -125% % -93%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 20,585,830 shares 308%
Entity Public Float $2,300,000 USD -60%
Common Stock, Value, Issued $0 USD

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $7,756,109 USD 129%
Nonoperating Income (Expense) $407,786 USD -36%
Net Income (Loss) Attributable to Parent $13,767,556 USD -58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,830,906 USD -41%
Assets, Current $6,015,330 USD -43%
Intangible Assets, Net (Excluding Goodwill) $408,334 USD -20%
Assets $6,423,664 USD -44%
Accounts Payable, Current $1,860,719 USD 736%
Accrued Liabilities, Current $2,157,581 USD 43%
Liabilities, Current $5,764,551 USD 66%
Other Liabilities, Noncurrent $1,873,733 USD -24%
Liabilities $7,638,284 USD 28%
Accumulated Other Comprehensive Income (Loss), Net of Tax $62,700,000 USD 24%
Retained Earnings (Accumulated Deficit) $66,622,074 USD -26%
Stockholders' Equity Attributable to Parent $1,214,620 USD -122%
Liabilities and Equity $6,423,664 USD -44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,594,179 USD -81%
Net Cash Provided by (Used in) Financing Activities $22,958 USD -100%
Net Cash Provided by (Used in) Investing Activities $2,770,000 USD
Common Stock, Shares Authorized 5,000,000,000 shares 4900%
Common Stock, Shares, Issued 20,585,830 shares 308%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,830,906 USD -41%
Deferred Tax Assets, Valuation Allowance $8,468,000 USD 36%
Deferred Tax Assets, Gross $8,468,000 USD 36%
Deferred Tax Assets, Operating Loss Carryforwards $5,683,000 USD 33%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $65,407,454 USD 12%
Amortization of Intangible Assets $100,000 USD -0.69%
Share-based Payment Arrangement, Expense $1,191,000 USD -3%